Investor Presentaiton

Research framework applied to Oncology builds on our scientific depth in tumor intrinsic mechanisms Strategy: Tumor Intrinsic Build a portfolio of foundational assets to address key tumor intrinsic and tumor extrinsic mechanisms, where combinations will be critical for durable responses with transformational potential. Oncogenic Mechanisms repotrectinib in ROS1+ lung cancer, RAS signaling (SHP2 inhibitor) Lineage-specific targets AR LDD in prostate cancer, anti-ganglioside fucosyl-GM1 in SCLC Cancer cell vulnerabilities Context specific dependencies (e.g., DNA damage), synthetic lethal interactions Oncogenic Drivers Lineage Specific DNA Damage Synthetic Lethal || || We have emerging expertise in tumor intrinsic biology Emerging clinical and pre-clinical programs targeted to specific tumor types and patient subsets Insights from translational datasets demonstrate the relationship between tumor intrinsic and tumor extrinsic to guide rational combinations Ill Bristol Myers Squibb™ Not for Product Promotional Use 24

View entire presentation